Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Among authors: alchami f. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
Retained basal cells in metastatic prostate cancer.
Varma M, Alchami FS, Griffiths DF. Varma M, et al. Among authors: alchami fs. Histopathology. 2016 Aug;69(2):338-40. doi: 10.1111/his.12928. Epub 2016 Feb 14. Histopathology. 2016. PMID: 26749042 No abstract available.
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, Barrett-Lee P, Alchami F, Piva M, Vivanco MD, Clarke RB, Gee J, Clarkson R. Piggott L, et al. Among authors: alchami f. Clin Cancer Res. 2018 May 15;24(10):2452-2463. doi: 10.1158/1078-0432.CCR-17-1381. Epub 2018 Jan 23. Clin Cancer Res. 2018. PMID: 29363524
Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells.
Chen HC, Joalland N, Bridgeman JS, Alchami FS, Jarry U, Khan MWA, Piggott L, Shanneik Y, Li J, Herold MJ, Herrmann T, Price DA, Gallimore AM, Clarkson RW, Scotet E, Moser B, Eberl M. Chen HC, et al. Among authors: alchami fs. Immunol Cell Biol. 2017 Aug;95(7):620-629. doi: 10.1038/icb.2017.21. Epub 2017 Mar 30. Immunol Cell Biol. 2017. PMID: 28356569 Free PMC article.
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN. Rosen LE, et al. Among authors: alchami fs. Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12. Mod Pathol. 2018. PMID: 29327706 Free article.
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.
Beresford M, Casbard A, Hudson Z, Carucci M, Ingarfield K, Gee J, Smith J, Kitson T, Alchami F, Madden TA, Hayward L, Hwang D, Spensley S, Waters S, Wheatley D, Jones RH. Beresford M, et al. Among authors: alchami f. BJC Rep. 2023 Sep 14;1(1):13. doi: 10.1038/s44276-023-00016-8. BJC Rep. 2023. PMID: 39516358 Free PMC article.
11 results